EC
SMMT icon

EntryPoint Capital’s Summit Therapeutics SMMT Stock Holding History

EntryPoint Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,186
Closed -$100K – 1562
2024
Q1 		$100K Buy
+24,186
New +$96.1K 0.09% 418

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EntryPoint Capital's SMMT Position: Q2 2024 in Review

EntryPoint Capital sold out of Summit Therapeutics (SMMT) in Q2 2024, closing a stake of 24,186 shares — an estimated $100K sold.

EntryPoint Capital first reported a position in SMMT in Q1 2024 and held it in 1 quarter. The position peaked at $100K in Q1 2024. 123 funds tracked by Wall St. Rank hold SMMT as of Q2 2024.

  • EntryPoint Capital reported no remaining Summit Therapeutics position as of Q2 2024 after selling out during the quarter.
  • EntryPoint Capital sold 24,186 Summit Therapeutics shares in Q2 2024, an estimated $100K.
  • EntryPoint Capital first reported a position in Summit Therapeutics in Q1 2024 and held it in 1 quarter.
  • EntryPoint Capital's Summit Therapeutics position peaked at $100K in Q1 2024.
  • 123 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.